Experience

Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the initial public offering by Notre Dame Intermédica and by Bain Capital, the controlling shareholder of…

Davis Polk advised the joint book-running managers in connection with a $36 million SEC-registered common stock offering by Aeglea BioTherapeutics, Inc. The common stock is listed on…

Davis Polk advised the representatives of the underwriters in connection with the $175 million public offering by Cellectis S.A. of 5,646,000 American Depositary Shares, each representing…

Davis Polk advised the lead book-running managers and representatives of the underwriters in connection with the SEC-registered offering of 4,000,000 shares of common stock of PTC…

Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 5.500% senior notes…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A offering by Accelerate Diagnostics, Inc. of $150 million aggregate principal amount of its 2…

Davis Polk advised Valeant Pharmaceuticals International, Inc. (“Valeant”) in connection with a refinancing transaction pursuant to which its indirect wholly owned subsidiary, Valeant…

Davis Polk advised the joint book-running managers in connection with the $226.3 million public offering of common stock of Xencor, Inc. The common stock is listed on the NASDAQ Global…

Davis Polk advised the joint book-running managers in connection with a $69 million SEC-registered common stock offering by Corvus Pharmaceuticals, Inc. The common stock is listed on the…

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with two SEC-registered follow-on offerings of common stock of Atara…